Topics

Astellas investigational treatment ASP1128 gains fast-track status

05:56 EDT 29 Oct 2019 | SmartBrief

Astellas Pharma's investigational therapy ASP1128 received fast-track designation from the FDA.  -More

Original Article: Astellas investigational treatment ASP1128 gains fast-track status

NEXT ARTICLE

More From BioPortfolio on "Astellas investigational treatment ASP1128 gains fast-track status"

Quick Search